Therapeutic IL-13 polypeptides

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9732133
SERIAL NO

15353273

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Variant IL-13 polypeptides are provided, which are engineered to have one or more of the following properties: (a) altered affinity for IL-13Rα2, relative to the native human IL-13 protein; (b) altered affinity for IL-13Rα1 relative to the native human IL-13 protein; (c) a disruption in the binding site for IL-4Rα relative to the native human IL-13 protein.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYOFFICE OF THE GENERAL COUNSEL BUILDING 170 THIRD FLOOR MAIN QUAD P O BOX 20386 STANFORD CA 94305-2038

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Garcia, Kenan Christopher Menlo Park, US 65 188
Gonzalez, Ignacio Moraga Palo Alto, US 10 9

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Feb 15, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 15, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00